drugset / Trial / NCT06117566
A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 combined with Toripalimab in patients with advanced solid tumors. The main questions it aims to answer are: * the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of WX390; * safety and preliminary in combined therapy. Participants will be treated with WX390 orally and Toripalimab intravenously, and follow the efficacy and safety evaluation according to the protocol.
Timeline
- Start
- 2022-11-18
- Primary completion
- 2025-11-09
- Completion
- 2025-11-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | WX390 | Unknown | 0.5 mg | Oral |
| Subject | WX390 | Unknown | 0.7 mg | Oral |
| Subject | WX390 | Unknown | 0.9 mg | Oral |